# MASLD Under the Umbrella of the Microbiota: A Narrative Review on Ecological Risk and Functional Transmissibility

**Authors:** Javier Crespo, Paula Argos Vélez, Marta Alonso-Peña, Lorena Cayón, Carolina Jiménez-González, Paula Iruzubieta

PMC · DOI: 10.3390/jcm15041325 · Journal of Clinical Medicine · 2026-02-07

## TL;DR

This review explores how gut microbiota may influence the development of liver disease, suggesting it could be functionally transmissible, not contagious.

## Contribution

The paper introduces the concept of MASLD as an eco-biological disease influenced by gut microbiota, not just genetics or environment.

## Key findings

- Gut microbiota can transfer susceptibility to liver disease in gnotobiotic animal models.
- Microbiota-targeted interventions in humans support the modifiable role of gut ecosystems in liver and metabolic health.
- MASLD risk is context-dependent and microbiota-mediated, not genetically inherited or contagious.

## Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease worldwide, distinguished by pronounced clinical heterogeneity and a frequent dissociation between metabolic risk factors and the degree of hepatic injury. These observations, together with the limited contribution of genetic heritability, have prompted a re-evaluation of the traditional conceptual framework of the disease. In this context, the question has emerged as to whether MASLD could be, at least in part, a transmissible condition. While there is no evidence to suggest that MASLD is contagious in humans, as no data support person-to-person transmission, gnotobiotic animal studies demonstrate that human gut microbiota can transfer susceptibility to steatosis, inflammation, and systemic metabolic disturbances through immunometabolic mechanisms, independent of host genetics. In parallel, human studies involving microbiota-targeted interventions support the concept that the gut ecosystem is a modifiable determinant of metabolic and hepatic phenotypes. Crucially, these findings do not imply natural transmission of disease, but rather underscore the functional plasticity of microbiota-host interactions. This narrative review integrates epidemiological, experimental, and clinical data to explore the hypothesis that MASLD may be functionally transmissible. MASLD is increasingly recognized as an eco-biological disease, where liver disease risk is not only shaped by host genetics and environment, but also by the ecological configuration and functional outputs of the gut microbiome. This perspective redefines disease susceptibility as, in part, context-dependent and microbiota-mediated, without implying infectiousness in the traditional sense.

## Linked entities

- **Diseases:** Metabolic dysfunction-associated steatotic liver disease (MONDO:0013209), MASLD (MONDO:0013209)

## Full-text entities

- **Genes:** SLC5A2 (solute carrier family 5 member 2) [NCBI Gene 6524] {aka SGLT2}, NR1H4 (nuclear receptor subfamily 1 group H member 4) [NCBI Gene 9971] {aka BAR, FXR, HRR-1, HRR1, PFIC5, RIP14}, CCR2 (C-C motif chemokine receptor 2) [NCBI Gene 729230] {aka CC-CKR-2, CCR-2, CCR2A, CCR2B, CD192, CKR2}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, GPBAR1 (G protein-coupled bile acid receptor 1) [NCBI Gene 151306] {aka BG37, GPCR19, GPR131, M-BAR, TGR5}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, FGF19 (fibroblast growth factor 19) [NCBI Gene 9965], CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, Nlrp6 (NLR family, pyrin domain containing 6) [NCBI Gene 101613] {aka Avr, Nalp6, Navr, Navr/Avr, Non-AVR, Pypaf5}
- **Diseases:** viral hepatitis (MESH:D014777), inflammasome deficiency (MESH:D007153), metabolic disturbances (MESH:D024821), endotoxemia (MESH:D019446), cirrhosis (MESH:D005355), hepatic inflammation (MESH:D007249), MASLD (MESH:D008107), injury to (MESH:D014947), hepatic insulin resistance (MESH:D007333), inflammatory, and immunological dysfunctions (MESH:C565684), dysbiosis (MESH:D064806), diabetes (MESH:D003920), infection (MESH:D007239), multiorgan failure (MESH:D051437), liver injury (MESH:D017093), hepatic disease (MESH:D056486), obese (MESH:D009765), hepatic decompensation (MESH:D006333), type 2 diabetes (MESH:D003924), MASH (MESH:D005234), Infectious (MESH:D003141), metabolic disease (MESH:D008659), hepatocellular carcinoma (MESH:D006528)
- **Chemicals:** IPA (MESH:C000723775), deoxycholic acid (MESH:D003840), bile acid (MESH:D001647), disulfiram (MESH:D004221), fatty acid (MESH:D005227), Vitamin E (MESH:D014810), choline (MESH:D002794), histidine (MESH:D006639), glycosphingolipids (MESH:D006028), imidazole propionate (MESH:C018976), butyrate (MESH:D002087), lipid (MESH:D008055), LPS (MESH:D008070), indoles (MESH:D007211), luminal (MESH:D010634), SCFA (MESH:D005232), ethanol (MESH:D000431), tryptophan (MESH:D014364), alcohol (MESH:D000438), acetate (MESH:D000085)
- **Species:** Homo sapiens (human, species) [taxon 9606], Klebsiella pneumoniae (species) [taxon 573], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940935/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940935/full.md

## References

81 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940935/full.md

---
Source: https://tomesphere.com/paper/PMC12940935